CN107530317A - 大麻素类和n‑酰基乙醇胺的组合 - Google Patents

大麻素类和n‑酰基乙醇胺的组合 Download PDF

Info

Publication number
CN107530317A
CN107530317A CN201680024534.5A CN201680024534A CN107530317A CN 107530317 A CN107530317 A CN 107530317A CN 201680024534 A CN201680024534 A CN 201680024534A CN 107530317 A CN107530317 A CN 107530317A
Authority
CN
China
Prior art keywords
pharmaceutical composition
cannabinoid
salt
acylethanolamine
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680024534.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·施穆勒维茨
E·哈勃
E·布雷纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scisparc Ltd
Original Assignee
Therapix Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapix Biosciences Ltd filed Critical Therapix Biosciences Ltd
Priority to CN202310678191.6A priority Critical patent/CN116549437A/zh
Publication of CN107530317A publication Critical patent/CN107530317A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
CN201680024534.5A 2015-04-29 2016-04-19 大麻素类和n‑酰基乙醇胺的组合 Pending CN107530317A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310678191.6A CN116549437A (zh) 2015-04-29 2016-04-19 大麻素类和n-酰基乙醇胺的组合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154144P 2015-04-29 2015-04-29
US62/154,144 2015-04-29
PCT/IL2016/050414 WO2016174661A1 (en) 2015-04-29 2016-04-19 Combinations of cannabinoids and n-acylethanolamines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310678191.6A Division CN116549437A (zh) 2015-04-29 2016-04-19 大麻素类和n-酰基乙醇胺的组合

Publications (1)

Publication Number Publication Date
CN107530317A true CN107530317A (zh) 2018-01-02

Family

ID=57199061

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680024534.5A Pending CN107530317A (zh) 2015-04-29 2016-04-19 大麻素类和n‑酰基乙醇胺的组合
CN202310678191.6A Pending CN116549437A (zh) 2015-04-29 2016-04-19 大麻素类和n-酰基乙醇胺的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310678191.6A Pending CN116549437A (zh) 2015-04-29 2016-04-19 大麻素类和n-酰基乙醇胺的组合

Country Status (12)

Country Link
US (7) US11234956B2 (https=)
EP (2) EP4193993A3 (https=)
JP (2) JP6938465B2 (https=)
CN (2) CN107530317A (https=)
AU (4) AU2016254685B2 (https=)
CA (1) CA2984088C (https=)
DK (1) DK3288553T3 (https=)
ES (1) ES2935605T3 (https=)
IL (2) IL291864A (https=)
MA (1) MA41997A (https=)
PL (1) PL3288553T3 (https=)
WO (1) WO2016174661A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4193993A3 (en) * 2015-04-29 2023-07-19 Scisparc Ltd. Combinations of cannabinoids and n-acylethanolamines
US20210052478A1 (en) * 2018-01-05 2021-02-25 Altus Labs, Llc Personal care compositions
US20220000833A1 (en) * 2018-01-29 2022-01-06 Therapix Biosciences Ltd. Compositions and methods for treating obstructive sleep apnea
EP3773512A4 (en) * 2018-04-03 2021-12-29 Pure Green, LLC Tablet or composition having n-acyl ethanolamine and cannabinoid
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
CA3136124C (en) * 2019-04-15 2024-04-09 Metagenics, Inc. Novel hemp and pea formulation and its use
AU2020263152A1 (en) * 2019-04-23 2021-10-21 SciISparc Ltd. Compositions and methods for potentiating derivatives of 4-Aminophenols
WO2020227440A1 (en) * 2019-05-07 2020-11-12 Ojai Energetics Pbc Methods for optimized cannabinoid dosage determination
EP3972573A4 (en) 2019-05-23 2023-07-12 India Globalization Capital, Inc. COMPOSITIONS AND METHODS OF USING CANNABINOIDS TO TREAT STAMMING/STOMMING AND SYMPTOMS OF TOURETTE SYNDROME
WO2021033149A1 (en) * 2019-08-19 2021-02-25 Buzzelet Development And Technologies Ltd. Compositons for the treatment of a condition characterized by anandamide deficiency and uses thereof
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
EP4087568A4 (en) 2020-01-10 2024-01-17 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
US20230080593A1 (en) 2020-01-10 2023-03-16 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
US11273122B2 (en) 2020-02-11 2022-03-15 Therese Mainella Combination of cannabis, derivatives thereof and additives in oral care compositions
BR112023013685A2 (pt) * 2021-01-11 2023-11-14 Pacira Pharmaceuticals Inc Tratamento da dor no quadril com composições anestésicas lipossômicas de liberação sustentada
WO2023278768A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
WO2023039419A2 (en) 2021-09-08 2023-03-16 Plantible Foods Inc. Systems and methods for measuring mat density of aquatic biomass
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
WO2024124354A1 (en) * 2022-12-16 2024-06-20 Aima Inc. Compositions and methods for treating or preventing pain or other disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173550A1 (en) * 1998-05-29 2002-11-21 Antonio Calignano Control of pain with endogenous cannabinoids
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
WO2007006319A2 (en) 2005-07-14 2007-01-18 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
KR101662871B1 (ko) * 2009-09-07 2016-10-05 에피테크 그룹 에스.알.엘. 초미세화 팔미토일-에탄올아미드를 함유한 조성물
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
EP4193993A3 (en) * 2015-04-29 2023-07-19 Scisparc Ltd. Combinations of cannabinoids and n-acylethanolamines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173550A1 (en) * 1998-05-29 2002-11-21 Antonio Calignano Control of pain with endogenous cannabinoids
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COPPOLA, M ET AL.: "Palmitoylethanolamide: From endogenous cannabimimetic substance", 《MEDICAL HYPOTHESES》 *
KIRSTEN R MU¨ LLER-VAHL ET AL；: "Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (DELTA9-THC): No influence on neuropsychological performance", 《NEUROPSYCHOPHARMACOLOGY》 *
RAHIMI, A ET AL.: "Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice", 《NEUROSCIENCE》 *

Also Published As

Publication number Publication date
EP4193993A3 (en) 2023-07-19
US20220071948A1 (en) 2022-03-10
IL255238B (en) 2022-05-01
US20210393577A1 (en) 2021-12-23
AU2021206784A1 (en) 2021-08-12
AU2021206784B2 (en) 2023-07-20
EP3288553A1 (en) 2018-03-07
JP2018514589A (ja) 2018-06-07
AU2016254685A1 (en) 2017-11-09
CA2984088C (en) 2024-04-09
WO2016174661A1 (en) 2016-11-03
MA41997A (fr) 2021-03-31
US20200030281A1 (en) 2020-01-30
US20180078523A1 (en) 2018-03-22
AU2016254685B2 (en) 2021-04-22
EP3288553A4 (en) 2018-12-26
EP3288553B1 (en) 2022-12-28
DK3288553T3 (da) 2023-01-23
CN116549437A (zh) 2023-08-08
PL3288553T3 (pl) 2023-03-20
ES2935605T3 (es) 2023-03-08
US20200038367A1 (en) 2020-02-06
JP2021107401A (ja) 2021-07-29
AU2023251426A1 (en) 2023-11-09
JP6938465B2 (ja) 2021-09-22
US11197845B2 (en) 2021-12-14
US11234956B2 (en) 2022-02-01
EP4193993A2 (en) 2023-06-14
US20220071949A1 (en) 2022-03-10
AU2023251426B2 (en) 2025-11-27
IL255238A0 (en) 2017-12-31
US11207290B2 (en) 2021-12-28
CA2984088A1 (en) 2016-11-03
US20200022946A1 (en) 2020-01-23
IL291864A (en) 2022-06-01
AU2025287414A1 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
AU2023251426B2 (en) Combinations of cannabinoids and N-acylethanolamines
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
AU2023251499B2 (en) Combinations of opioids and N-acylethanolamines
EA038052B1 (ru) Комбинация, содержащая пальмитоилэтаноламид, для лечения хронической боли
Schutz et al. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat
MX2009002311A (es) Composiciones farmaceuticas para tratamiento de infecciones fungales.
CN102821760B (zh) 用于治疗神经退行性变疾病或神经血管疾病的新型药物组合物
JP2011121975A (ja) 線維筋痛症に伴う疼痛を改善するための線維筋痛症に伴う疼痛改善用医薬組成物
JP6084931B2 (ja) ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
HK40085288A (en) Combinations of cannabinoids and n-acylethanolamines
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
IL230174A (en) Pharmaceutical composition for the treatment of premature ejaculation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Israel Tel Aviv

Applicant after: Sespak Co.,Ltd.

Address before: Israel Tel Aviv

Applicant before: THERAPIX BIOSCIENCES Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180102